Shares of the Ahmedabad-based biopharma company, which listed a few weeks ago at a more than 20% premium, have notched another 9% gain since then. The shares topped ₹1,000 in intraday trade on Friday, before closing nearly 2% higher on the NSE at ₹983.40.
Concord Biotech’s niche strengths seen buoying earnings: Analysts
Date:
More like thisRelated
President Trump’s “Weaponization” Executive Order
President Trump signed another executive order, titled "Ending the...
Trump Signals a Crackdown on Legal and Illegal Immigration
The president plans to suspend refugee resettlement and declare...
Trump Goes After Mexico by Designating Drug Cartels Terrorist Organizations
Designating cartels as terrorist organizations could allow the feds...